Lesson of the week. Oxybutynin and cognitive dysfunction

British Medical Journal

Volumn 315, Issue 7119, 1997, Pages 1363-1364

  Donnellan, C A ^a   Fook, L ^a   McDonald, P ^a   Playfer, J R ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIPARKINSON AGENT; BECLOMETASONE DIPROPIONATE; BELLADONNA ALKALOID; BROMOCRIPTINE; CLOMETHIAZOLE; CO BENELDOPA; DILTIAZEM; FUROSEMIDE; ISOSORBIDE MONONITRATE; NAFTIDROFURYL OXALATE; OXYBUTYNIN; PREDNISOLONE; RANITIDINE; SALBUTAMOL; SELEGILINE; THEOPHYLLINE; UNCLASSIFIED DRUG; CHOLINERGIC RECEPTOR BLOCKING AGENT; MANDELIC ACID DERIVATIVE;

AGED; ARTICLE; CASE REPORT; COGNITIVE DEFECT; CONFUSION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PARANOIA; PARKINSON DISEASE; PRIORITY JOURNAL; VISUAL HALLUCINATION; CHEMICALLY INDUCED DISORDER;

AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; CONFUSION; HUMANS; MALE; MANDELIC ACIDS; PARKINSON DISEASE;

EID: 0031583646     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.315.7119.1363     Document Type: Article

References (13)

1. Koyanagi T, Maru A, Taniguchi K, Shinno V, Takamatsu T, Morita H, et al. Clinical evaluation of oxybutynin hydrochloride tablets for the treatment of neurogenic bladder and unstable bladder. A parallel double-blind controlled study with placebo. Nishinthon J Urol 1986;48:1052-72.
2. Malone-Lee J, Lubel D, Szonyi G. Low dose oxybutynin for unstable bladder. BMJ 1992;304:1053.
3. Ouslander JG, Blausten J, Connor A, Orzeck S, Yong CL. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988;140:47-50.
4. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-7.
5. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. No 34. London: BMA, RPS, 1997.
6. Arendt T, Bidl V, Arendt A, Tennstedt A, Loss of neurons in the nucleus basalias of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol 1983;61:101-8.
7. Lange KW, Wells FR, Jenner P, Marsden CD. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neurochem 1993;60:197-203.
8. Perry RH, Tomlinson BE, Candy JM, Blessed G, Foster JF, Bloxham CA. Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet 1983;ii:789-90.
9. Rabney JM, Gryberg E, Graff E. Changes in muscarinic cholinergic binding by lymphocytes in Parkinsons disease with and without dementia. AnnNeurol 1991;30:847-50.
10. Asahina M, Shinotoh H, Hirayama K, Suhara T, Shihido F, Inoue O, et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET Acta Neurol Scand 1995;91:437-43.
11. Perry EK, Perry RH, Smith CJ, Purohit D, Bonham J, Dick DJ, et al. Cholinergic receptors in cognitive disorders. Can J Neurol Sci 1986;13(suppl 4):521-7.
12. Peitzko A, Dimpfel W, Schwantes U, Toplmeier P. Influentes of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmcol 1994;47:337-43.
13. Mitchelson F. Muscarinic receptor differentiation. Pharmacol Ther 1988;37:357-423.